

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT8310815

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
JACQUELINE M. IVERSEN	01/31/2018
THOMAS A. DAHL	01/31/2018
RECEIVING PARTY DATA	
Name:	SEN-JAM PHARMACEUTICAL LLC
Street Address:	223 WALL STREET
Internal Address:	#130
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	11743
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16897849
CORRESPONDENCE DATA	
Fax Number:	(202)739-3001
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	202-739-3000
Email:	phpatentcorrespondence@morganlewis.com, amanda.mcintyre@morganlewis.com
Correspondent Name:	MORGAN, LEWIS, & BOCKIUS LLP (B0)
Address Line 1:	2222 MARKET STREET
Address Line 4:	PHILADELPHIA, PENNSYLVANIA 19103
ATTORNEY DOCKET NUMBER:	SJ-002/119887-5002
NAME OF SUBMITTER:	JIA JIE TANG
SIGNATURE:	/Jia Jie Tang/
DATE SIGNED:	12/05/2023
Total Attachments: 2	
source=SJ-002_Executed_Assignment#page1.tif	
source=SJ-002_Executed_Assignment#page2.tif	

PATENT ASSIGNMENT

This Patent Assignment is made by Jacqueline M. Iversen of Lloyd Harbor, New York and Thomas A. Dahl of Guilford, Connecticut (hereinafter collectively “the INVENTORS”) in favor of SEN-JAM Pharmaceutical LLC., a limited liability company duly organized and existing under the laws of the State of Delaware, having its principal place of business at 223 Wall Street, #130 Huntington, New York 11743 (hereinafter “SEN-JAM”). The INVENTORS and SEN-JAM are collectively referred to herein as “the Parties”.

WHEREAS the INVENTORS own the entire worldwide right, title, and interest in U.S. Provisional Patent Application No. 62/520,857 filed June 16, 2017, and entitled Methods and Compositions to Inhibit Symptoms Associated with Viral Upper Respiratory Tract Infections, and the inventions related thereto (hereinafter referred to as the “Patent Property”);


WHEREAS SEN-JAM desires to acquired the entire right, title, and interest in the Patent Property from the INVENTORS.

NOW THEREFORE, for good and valuable consideration of the sum of ten U.S. Dollars (\$10.00) and other valuable consideration, the receipt and sufficiency of which is hereby mutually acknowledged, the INVENTORS do hereby irrevocably sell, assign, transfer, and convey to SEN-JAM, its successors and assigns, all right, title and interest in and to the Patent Property for the United States and elsewhere throughout the world, and all rights in any patents or provisional or nonprovisional applications claiming priority thereto including without limitation all divisionals, continuations, continuations- in-part, re-examinations, re-issues and extensions of the Patent Property, and any foreign equivalents thereto, and any improvement to the inventions related to the Patent Property, all rights to claim priority, and all right to fully exploit, receive royalties and compensation of any kind and to enforce all infringement claims in respect to any of the Patent Property.

The INVENTORS hereby covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment.

The INVENTORS agree to execute and promptly deliver at the request of SEN-JAM, all papers, instruments and assignments, and to perform any other reasonable acts SEN-JAM may require in order to vest all right, title and interest in and to the Patent Property, in SEN-JAM and/or SEN-JAM 's successor and/or to provide evidence to support any of the foregoing in the event such evidence is deemed necessary by SEN-JAM and/or SEN-JAM's successor, to the extent such evidence is in the possession or control of the INVENTORS:

IN WITNESS WHEREOF, the INVENTORS do hereby execute this Patent Assignment.



Jacqueline M. Iversen

Dated: 1/31/18.




Thomas A. Dahl

Dated: 31JAN2018

Accepted and Acknowledged

SEN-JAM Pharmaceutical LLC

By: 

Name: James M. Iversen

Title: CEO

Dated: 1/31/18